Approval · Notice of Compliance 37525 · 2026
SUPREFACT: Notice of Compliance 37525
Issued May 11, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37525
- Date
- May 11, 2026
- Company
- Cheplapharm Arzneimittel GmbhGreifswald, Mecklenburg - West Pomerania, Germany
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a manufacturing site and/or manufacturer involving production of the drug substance. Addition of a drug product manufacturing site and/or manufacturer involving production. Change in the composition of a dosage form. Change in the drug product manufacturing process. Addition of a primary container closure system. Addition of a drug product manufacturing site and/or manufacturer involving primary packaging. Update to package labels
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUPREFACT | Not yet assigned | — |
Medicinal ingredients
- BUSERELIN ACETATE 1 MG per ML